Company: ZVRA
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001437749-25-016523
Chunk: 12

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 8
Chunk 12
---
 this guidance will have on the presentation of its financial statements and accompanying notes.

    C.  Segment Information 

   Zevra manages its business activities on a consolidated basis and operates as a single operating segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. The Company primarily derives its revenue from reimbursements received from product sales of MIPLYFFA and OLPRUVA, reimbursements received under the French AC, royalties or net sales milestone payments generated under the AZSTARYS License Agreement, and consulting agreements. The accounting policies of the segment are the same as those described in Note B.
    
   Zevra's CODM is the Company's Chief Executive Officer, Neil F. McFarlane. The CODM uses net loss, as reported in the Company's unaudited condensed consolidated statements of operations, in evaluating performance of its segment and determining how to allocate resources of the Company as a whole, including investing in its research and development, commercialization efforts, and acquisition strategy. The CODM does not review assets in evaluating the results of the segment, and, therefore, such information is not presented.
    
    The following table presents the operating results of the Company's segment:

       Three months ended March 31,  
   2025    2024  
 Total revenues  $20,401  $3,425 
 Less significant segment expenses:         
 Research and development directly identified to programs   2,361   7,211 
 Research and development not directly identified to programs   897   5,066 
 Selling, general and administrative directly identified to programs   7,561   3,862 
 Selling, general and administrative not directly identified to programs   11,984   6,069 
 Other segment items:         
 Income tax expense (benefit)   1,182   (70)
 Interest income   (718)  (762)
 Depreciation and amortization expense   1,649   1,562 
 Interest expense   1,969   735 
 Other income, net(a)   (3,385)  (3,626)
 Segment net loss  $(3,099) $(16,622)

   (a) Other expense, net included in segment net loss includes foreign currency exchange gains and losses, cost of product revenue (excluding intangible asset amortization),